<DOC>
	<DOCNO>NCT00118326</DOCNO>
	<brief_summary>RATIONALE : A bone marrow transplant brother sister may able replace blood-forming cell destroy chemotherapy radiation therapy . Colony-stimulating factor , G-CSF , cause body make blood cell . Giving G-CSF donor may help body make stem cell collect bone marrow transplant may cause few side effect patient transplant . PURPOSE : This phase I/II trial study side effect donor bone marrow transplant see well work treat young patient cancer non-cancerous disease .</brief_summary>
	<brief_title>Donor Bone Marrow Transplant Treating Young Patients With Cancer Non-Cancerous Disease</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety feasibility filgrastim ( G-CSF ) -mobilized bone marrow HLA-identical pediatric sibling donor stem cell source pediatric patient undergo allogeneic bone marrow transplantation malignant non-malignant disease . Secondary - Determine time neutrophil platelet engraftment , number red blood cell platelet transfusion , number febrile day , number hospitalization day patient treated regimen . - Determine number nucleate cell CD34-positive cell , absolute lymphocyte count , lymphocyte subset ( CD3/CD4/CD8 ) G-CSF-mobilized bone marrow donor . OUTLINE : This multicenter , pilot study . Donors receive filgrastim ( G-CSF ) subcutaneously daily day -4 0 . Donors undergo standard bone marrow harvest day 0 . Patients receive pre-transplantation condition graft-versus-host disease prophylaxis accord disease patient treat treatment plan clinical trial patient enrol . Patients undergo allogeneic bone marrow transplantation day 0 . After completion bone marrow harvest , donor follow 7 30 day . After completion study treatment , patient follow 100 day post-transplantation periodically thereafter . PROJECTED ACCRUAL : A total 80 participant ( 40 donor 40 patient ) accrue study within 18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients ( recipient ) : Undergoing myeloablative nonmyeloablative allogeneic bone marrow transplantation 1 follow disease : Hematologic malignancy Nonhematologic malignancy Nonmalignant disease Not undergo Tcell deplete bone marrow transplantation Donors : Healthy sibling patient meeting eligibility requirement protocol HLAidentically match patient PATIENT CHARACTERISTICS : Age 18 ( patient donor ) Performance status Karnofsky 90100 % ( donor ) OR Lansky 90100 % ( donor ) Life expectancy Not specify Hematopoietic No sickle cell anemia ( donor ) Hepatic Not specify Renal Not specify Immunologic HIV negative ( patient donor ) No uncontrolled bacterial , viral , fungal , parasitic infection ( donor ) No potentially life threaten autoimmune disease ( donor ) Other Not pregnant nursing ( patient donor ) Fertile patient must use effective contraception ( patient ) No illness would severely limit life expectancy ( patient ) No preexist medical condition would confer high risk bone marrow donation ( donor ) No medical condition psychiatric trait would preclude GCSF administration bone marrow harvesting ( donor ) PRIOR CONCURRENT THERAPY : Biologic therapy More 4 year since prior allogeneic blood transfusion ( donor ) No concurrent growth factor posttransplantation ( donor ) Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Concurrent participation another treatment clinical trial allow provide use filgrastim ( GCSF ) mobilize bone marrow exclude ( patient ) No concurrent investigational agent ( donor )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
</DOC>